Dong-A ST Out License NESP® Biosimilar DA-3880 to Polifarma of Türkiye

Dong-A ST (Min Young Kim, President and CEO) (KRX: 170900) announced that they signed an exclusive license-out and supply agreement on November 4, 2022, with Polifarma (Mehmet Asri, CEO) for NESP® biosimilar DA-3880. According to the agreement, Dong-A ST will license out the exclusive rights for the development and commercialization of DA-3880 in Türkiye, Brazil, and Mexico to Polifarma. Dong-A ST will receive upfront and developmental/commercial milestone payments and will exclusively supp…


– 출처 : https://www.newswire.co.kr/newsRead.php?no=955311&sourceType=rss

함께 보면 좋은 콘텐츠